3 Largecap Steady 1-year Gainer Stocks to Watch for Future Multibagger Potential: Titan, Divi's Labs and Torrent Pharma

Steady 1-year gainer stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Titan, Divi's Labs and Torrent Pharma meet that test, with market caps from Rs 1.75 lakh crore to Rs 3.95 lakh crore and Titan offering the highest return on equity at 32.31%. Each of these large companies has gained between 20 and 60 per cent in the past year without extreme swings.

This list covers large companies whose share price has risen by 20 to 60 per cent over one year, with rising profit and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening steady 1-year gainer stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 16 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are Steady 1-year Gainer Stocks and Why Do They Attract Multibagger Interest?

Steady 1-year gainer stocks are shares of large companies that have delivered solid returns over twelve months. Gains of this size, backed by rising profit, often show a business that is compounding steadily instead of racing ahead of its earnings.

A steady climb usually comes with growing sales and profit, rather than a sudden jump in sentiment. Companies that keep growing profit from here are the ones investors compare in steady 1-year gainer stocks.

Steady 1-year Gainer Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are closing prices as of 16 October 2026. Titan combines the lowest PE of the group, 68.51, with the highest return on equity, 32.31%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Debt to Equity	52-Week Range (Rs)
Titan Company	4,444.80	3,94,621	68.51	46.75	32.31%	0.93	3,506.50 to 5,186.70
Divi's Laboratories	9,144.50	2,39,982	82.05	36.42	15.32%	0.00	5,647.50 to 9,740.00
Torrent Pharmaceuticals	4,558.90	1,75,196	81.26	36.42	25.49%	1.79	3,480.60 to 5,250.00

Titan: 23.26% Profit CAGR Since FY22

Titan Company runs the jewellery (Tanishq), watches (Titan), eyewear and fragrances businesses. It reported FY26 revenue of Rs 88,136 crore, up 44.62% year on year, and net profit of Rs 5,073 crore, up 52.02%. Net profit has compounded at 23.26% a year since FY22, while revenue has grown 32.00% a year. Operating margin was 10.06% in FY26.

In the June 2026 quarter, revenue rose 29.31% to Rs 21,502 crore and net profit grew 62.88% to Rs 1,777 crore. The share price has gained 72.39% over five years and 22.47% over the past year. Domestic institutions raised their holding from 12.78% in June 2025 to 15.34% in June 2026. The stock trades at a PE of 68.51 against an industry PE of 46.75, with a return on equity of 32.31%.

Divi's Labs: Debt-to-Equity of 0.00

Divi's Laboratories makes active pharmaceutical ingredients and intermediates and runs a large custom synthesis business for global drug companies. It reported FY26 revenue of Rs 11,067 crore, up 13.95% year on year, and net profit of Rs 2,568 crore, up 17.21%. Revenue has compounded at 5.09% a year since FY22. Operating margin was 36.70% in FY26. The debt-to-equity ratio is 0.00, which keeps interest costs low.

The stock trades at a PE of 82.05 against an industry PE of 36.42, with a return on equity of 15.32%. In the June 2026 quarter, revenue rose 24.32% to Rs 3,144 crore and net profit grew 65.50% to Rs 902 crore. The share price has gained 71.04% over five years and 38.43% over the past year. Foreign investors raised their holding from 19.39% in September 2025 to 20.38% in September 2026.

Torrent Pharma: 28.79% Profit CAGR Since FY22

Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.

In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 194.63% over five years and 29.72% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026. The stock trades at a PE of 81.26 against an industry PE of 36.42, with a return on equity of 25.49%.

Steady 1-year Gainer Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these steady 1-year gainer stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	Latest Quarter Revenue Growth	Operating Margin (Latest Quarter)
Titan	88,136	5,073	44.62%	32.00%	29.31%	14.61%
Divi's Labs	11,067	2,568	13.95%	5.09%	24.32%	42.82%
Torrent Pharma	13,886.15	2,138.18	20.34%	12.38%	56.29%	33.73%

Check the Univest Screener for live data on these steady 1-year gainer stocks

Institutional Holding in Titan, Divi's Labs and Torrent Pharma

Institutional holding shows who is backing these steady 1-year gainer stocks alongside the promoter. The table uses the latest reported quarter for each. Divi's Labs has the deepest institutional backing, with FII and DII together holding 39.55% as of September 2026. Domestic institutions increased their holding over the past year in Titan (from 12.78% to 15.34%) and Torrent Pharma (from 9.28% to 12.87%).

Stock	Promoter	FII	DII	Public	Quarter
Titan	52.90%	15.38%	15.34%	16.38%	June 2026
Divi's Labs	51.88%	20.38%	19.17%	8.58%	September 2026
Torrent Pharma	60.78%	17.97%	12.87%	8.38%	July 2026

Risks to Weigh in Steady 1-year Gainer Stocks

Being careful with steady 1-year gainer stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past returns do not guarantee future gains.
• Compare valuation with growth before investing.
• Valuation: Divi's Labs trades at a PE of 82.05 against an industry PE of 36.42, so earnings need to keep growing to support the price.
• Concentration: Holding all 3 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between Steady 1-year Gainer Stocks

Picking from steady 1-year gainer stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (36.42 to 46.75) and ask whether the growth rate justifies any gap.
3. Track quarterly profit growth, the return on equity and the valuation in every result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Titan, Divi's Labs and Torrent Pharma live prices.

Conclusion

Among steady 1-year gainer stocks, Titan stands out for the highest return on equity at 32.31%, Divi's Labs for the strongest latest-quarter profit growth at 65.50% and Torrent Pharma for the fastest profit growth, 28.79% a year since FY22. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing steady 1-year gainer stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Steady 1-year Gainer Stocks to Watch

Which are the best steady 1-year gainer stocks to watch for multibagger potential?

Ans. Titan, Divi's Labs and Torrent Pharma are the 3 names this list highlights, with market caps of Rs 3,94,621 crore, Rs 2,39,982 crore and Rs 1,75,196 crore respectively. Titan is notable for the highest return on equity at 32.31%. Divi's Labs stands out for the strongest latest-quarter profit growth at 65.50%. Torrent Pharma offers the fastest profit growth, 28.79% a year since FY22. These are watchlist names for steady 1-year gainer stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Titan a good stock for long-term investors?

Ans. Titan has a return on equity of 32.31%, a PE of 68.51 against an industry PE of 46.75 and a market cap of Rs 3,94,621 crore. Net profit has compounded at 23.26% a year since FY22, and FY26 revenue rose 44.62% while June 2026 quarter net profit grew 62.88%. Long-term returns in steady 1-year gainer stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Torrent Pharma become a multibagger from here?

Ans. Torrent Pharma has already gained 194.63% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in steady 1-year gainer stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34%. At a PE of 81.26 against an industry PE of 36.42, valuation should be checked against that growth before investing.

What is the market cap of Titan, Divi's Labs and Torrent Pharma?

Ans. As of 16 October 2026, Titan has a market cap of Rs 3,94,621 crore, Divi's Labs has a market cap of Rs 2,39,982 crore and Torrent Pharma has a market cap of Rs 1,75,196 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on steady 1-year gainer stocks.

What are the risks of investing in steady 1-year gainer stocks?

Ans. The main risks are profit booking after gains, valuations that already reflect growth and a change in market mood. Companies with steady earnings and strong brands handle these better. Divi's Labs trades at a PE of 82.05 against an industry PE of 36.42, so earnings growth needs to hold up.

Why is Divi's Labs trading at a PE of 82.05?

Ans. Divi's Labs' PE of 82.05 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 15.32% and latest-quarter profit growth of 65.50%, which also means the stock is more sensitive if growth slows. Investors in steady 1-year gainer stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in Titan, Divi's Labs and Torrent Pharma?

Ans. As of the latest reported quarter, FII and DII together hold 30.72% of Titan (15.38% and 15.34%), 39.55% of Divi's Labs (20.38% and 19.17%) and 30.84% of Torrent Pharma (17.97% and 12.87%). Rising institutional holding is a useful signal in steady 1-year gainer stocks, though it should be read with earnings trends rather than on its own.